SCI — Investor Presentation 2019

Jan 18, 2019

SCI PHARMTECH, ING.

簡報

procedure Thainform Forwardterium Leola

All-HescoryList.Count > 0 these Forwardten inn, Enchind in Michon

Xol ardAckion, Enabled a False and r

CLOSE EXOTORIC + Teres, NYL !! Store population Prosentern Mobile which I is coast plasp: Dispatch, var MII Reading at OleVariable r-way

d destoryTodes + 01 MALDE HARGOLYLAST COMME . HAR I dioryLift Delate Office or 97 Highlip Ladas in Ristory List. Add

DES

RicertyTodes is Newtodes: ar brownsteads then hegin

Doctor Course I'm Falue.

Mel Andex ; a UEZ; Ituna, Index02

AE MANDICON - - 1 About

UP J. ftems, Promer (0, U914

員工數Employee:254 設立日期:中華民國七十六年九月十八日 Date of establishment: Sep. 18, 1987 資本額Capital:新台幣795佰萬元(NTD 795mn) 營業項目Business: 原料藥API(61.81%) 中間體Intermediate(30.09%) 特用化學品 Custom-made chemicals(8.10%)

公司概況Outline

	Y2018	Y2017
歐 洲Europe	40.80%	42.07%
洲America 美	31.21%	21.29%
亞 洲Asia	14.94%	21.37%
國 內Taiwan	11.02%	14.21%
其 他 others	2.03%	1.06%
合 計Total	100.00%	100.00%

Unit: K NTD

	Jan~Nov, 2018Y	2017Y
營收Sales	1,807,377	1,301,050
營業成本COGS	(1,111,373)	(906,694)
毛利Gross Profit	696,004	394,356
毛利率 GP Ratio	38.5%	30.3%
營業費用Operating Expenses	(221,590)	(161,307)
營業利益Operating Income	474,414	233,049
營業外損益Non-Operating In/Ex	31,316	1,725
稅前淨利 Net Profit before Tax	505,730	234,774
所得稅Income Tax	-	(43,798)
本期淨利Net Profit after Tax	505,730	190,976

產品組合-Products

Y2016	%	Y2017	%	Y2018	%
HOCLQ Sulfate	34.94	S-MMAA / Dulo	13.14	HOCLQ Sulfate	22.29
PGA	12.73	VA Series	12.48	VA Series	16.70
VA Series	13.55	HOCLQ Sulfate	12.47	S-MMAA / Dulo	12.57
S-MMAA / Dulo	5.32	LPF.Na	9.41	PGA	9.64
Pent-2 / PEB.Na	6.70	PGA	9.22	Pent-2 / PEB.Na	6.68
5-HMT / 5-Wing	5.21	Pent-2 / PEB.Na	8.69	PMDOL / Olivetol	5.80
LPF.Na	4.01	5-HMT / 5-Wing	6.26	5-HMT / 5-Wing	2.95
Total	82.46	Total	71.67	Total	76.63

SCI PHARMTECH, INC.

SCI

Product	$\%$	Y2018 (NT\$)
HOCLQ Sulfate	22.3	432,352,052
VA series	16.7	323,973,912
S-MMAA / Dulo	12.6	243,922,769
PGA	9.6	186,983,691
Pent-2 / PEB.Na	6.7	129,657,548
Olivetol / PMDOL	5.8	112,513,665
$5-HMT / 5$ -wing	3.0	57,264,767

重點產品介紹 Product Profile

• Hydroxychloroquine Sulfate
• (S)-MMAA / Duloxetine HCl
• VA / DiVANa / NaVA
• Menthadienol / Olivetol / Ethyl Olivetolate
• Brinzolamide
• Benzhydrylamine / 3-Azetidinol
• Ritalinic acid / Methylphenidate
• d-Ritalinic acid / Dexmethylphenidate

Hydroxychloroquine sulfate

適應症 Application:

類風濕性關節炎(rheumatoid arthritis) 、瘧疾 (malaria)、 慢性多形性日光疹、慢性圓板狀紅斑症 (discoid and

systemic lupus erythematosus)

VA Series:

Valproic Acid, Divalproex Sodium, Sodium Valproate

適應症 Application: 癲癇(seizure)、躁鬱症(bipolar disorder)、 偏頭痛(migraine headaches)

S-MMAA/Duloxetine HCl

適應症 Application: 重鬱症(major depressive disorder)、廣泛性焦慮症 (generalized anxiety disorder) 、糖尿病週邊神經痛 (diabetic neuropathy) 、纖維肌痛(Fibromyalgia)、 慢性腰痛(日本地區) lower back pain (only in Japan)

Pyrogallolaldehyde ( PGA) - Benserazide 治療帕金森氏症之中間體

Intermediate for Parkinson's Disease

Pent-2 / Pentobarbital Sodium

鎮定安眠用中間體及原料藥 Intermediate and API for calmative

Menthadienol, Olivetol, Ethyl Olivetolate (1)

• 1. Dronabinol 之關鍵中間體 Key intermediate of Dronabinol 適應症 Applications:
• 化療引起的噁心、嘔吐 Nausea and vomiting due to chemotherapy
• 愛滋病引起之厭食症 anorexia due to AIDS

Menthadienol, Olivetol, Ethyl Olivetolate (2)

• 1. Cannabidiol (CBD, 大麻二酚)之關鍵中間體 Key intermediate of CBD
• CBD之應用廣泛:癲癇、巴金森氏症、阿茲海默症、躁鬱 、焦慮、止 痛、抗發炎等。
• 與THC(四氫大麻酚)不同,CBD沒有其精神副作用及成癮性。
• FDA 於 6/25 批准 Epidiolex (GW之大麻二酚新藥),適用於兒童的兩種 罕見癲癇以及多發性硬化症,開啟了大麻衍生藥物療法的新紀元。
• CBD has a wide range of medical benefits, helping with issues like epilepsy, Parkinson's and Alzheimer's disease, bipolar disorder, anxiety, pain, inflammation, etc.
• Unlike THC, CBD has no intoxicating effects.
• FDA approved Epidiolex (new drug of GW) on June 25, for seizures associated with Lennox-Gastaut syndrome (LGS) and Dravet syndrome in patients aged 2 years and older, and Multiple Sclerosis. This has became a milestone of Cannabinoids derivatives.

Brinzolamide

• 適應症 Application:青光眼 (glaucoma)
• 單方:Brinzolamide
• 複方:Brinzolamide+Timolol,

Brinzolamide+Brimonidine tartrate

製劑需求量 (FDF consumption): ~2MT, US\$ 6.3億 (9/30/2016~9/30/2017)。

Benzhydrylamine / 3-Azetidinol

適應症 Application:降血壓 (hypertension)、新抗生素 (new antibiotics)、新阿茲海默症中間體 (intermediate used for new Alzheimer treatment)

Ritalinic acid / Methylphenidate (MEPH) d-Ritalinic acid / Dexmethylphenidate (dex-MEPH)

適應症 Application: 注意力不足 (attention deficit hyperactivity disorder (ADHD) 、過動症 (narcolepsy) MEPH 製劑需求量 (FDF consumption): 38MT, US\$ 32.4億 (9/30/2016~9/30/2017)。 Dex-MEPH製劑需求量需求量 (FDF consumption): 2.4MT, US\$ 7億 (9/30/2016~9/30/2017) 。

新市場 (New Market):

與印度、中國 、俄羅斯及新興國家之合作 Partner with India, China, Russia and Emerging countries

1) 大麻二酚 (CBD) 2) 中樞神經用藥 (CNS) 3) 失智症 (dementia) 4) 癌症用藥 (oncology) 5) 管制藥 (controlled substance) 新藥方向 (New drugs):

SCI PHARMTECH, INC.

No.	API	DMF (USA)	CEP (EDQM)	MF (Japan)	DMF (Canada)	CGMP certified (TFDA)
$\blacktriangleleft$	Valproic Acid	2003	2004	2008	2008	2003
2 1	Probucol	2004		2017	2015	2015
3	Divalproex Sodium	2005			2010	2005
4	Propafenone Hydrochloride	2010	2012	2012	2012	2010
5 5	Duloxetine Hydrochloride	2011	2014	2017	2016	2012
6 °	Allopurinol	2011	2003			2004
$\overline{7}$	Clindamycin Palmitate HCI	2011
8	Articaine Hydrochloride	2014	2016			2013
9 °	Hydroxychloroquine Sulfate	2014			2014	2014
10	Brinzolamide	2015		2017		2015
11	Sodium Valproate		2006	2017		2004
12 2	Pentobarbital Sodium		2011			2009
13	Methylphenidate HCI		2014			2011
14	Bisoprolol Fumarate					2006
15	Thiopental acid					2012
16	Loxoprofen Sodium Hydrate			2011		2012
17	Atomoxetine HCI					2016

SCI

敬 請 指 教